Current Research Studies
Post-trial Access Program: Idursulfase-IT (HGT-2310) in Conjunction with Intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cognitive Impairment
TAK609 PTA
What is the goal of the study?
This is a post trial access program to continue to allow continued study drug (intrathecal idursulfase) access for our Hunter Syndrome patients that were previously enrolled in the HGTHIT046 trial.
Who can participate in the study?
Please contact the study team listed below to learn more.